Additional Relevant Details Cytokinetics, in partnership with Astellas Pharmaceuticals, initiated a Phase 2 study of its drug CK-2127107 used to treat spinal muscular atrophy (SMA).  The clinical trial is designed to assess effects of CK-2127107 on multiple measures of muscle function in both ambulatory and non-ambulatory patients with SMA. a severe, genetic neuromuscular disease that leads to debilitating muscle wasting and progressive, often fatal, muscle weakness.  Study is projected to be completed and results released in mid-2017.